



IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	Application Number		10/644,410
	Filing Date		August 20, 2003
	First Named Inventor		Jay M. Short
	Art Unit		
	Examiner Name		
Total Number of Pages in This Submission	11	Attorney Docket Number	D1460-32US

### ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): <div style="margin-left: 20px;">6 non-patent references Return post card</div>
Remarks		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name			
Signature			
Printed name	Calvin Fan (for Diversa Corporation, Customer No. 29062)		
Date	October 12, 2005	Reg. No.	38,444

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Calvin Fan		
Date	October 12, 2005		

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Publication Date (MM-DD-YYYY)	Document No. Number-Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	09/90	4,959,312	Sirotkin	
	2.	06/91	5,023,171	Ho et al.	
	3.	03/92	5,096,815	Ladner et al.	
	4.	03/93	5,198,346	Ladner et al.	
	5.	06/93	5,223,409	Ladner et al.	
	6.	01/94	5,279,952	Wu	
	7.	02/95	5,389,537	Raines et al.	
	8.	03/96	5,498,531	Jarrell	
	9.	08/97	5,658,727	Barbas et al.	
	10.	06/98	5,759,817	Barbas	
	11.	08/98	5,789,166	Bauer et al.	
	12.	10/98	5,824,485	Thompson et al.	
	13.	02/99	5,866,363	Pieczenik	
	14.	03/99	5,885,577	Alvarez	
	15.	03/99	5,885,827	Wabl et al.	
	16.	08/99	5,932,419	Bauer et al.	
	17.	08/99	5,945,329	Breddam et al.	
	18.	08/00	6,096,548	Stemmer	
	19.	09/00	6,117,679	Stemmer	
	20.	12/00	6,165,793	Stemmer	
	21.	01/01	6,180,406	Stemmer	
	22.	08/01	6,277,638	Stemmer	
	23.	09/01	6,291,158	Winter et al.	
	24.	11/01	6,319,714	Cramer et al.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

25.	11/01	6,323,030	Stemmer	
26.	01/02	6,335,160	Patten et al.	
27.	01/02	6,337,186	Krebber	
28.	02/02	6,344,356	Stemmer	
29.	04/02	6,365,408	Stemmer	
30.	04/02	6,368,861	Crameri et al.	
31.	04/02	6,372,497	Stemmer	
32.	04/02	6,376,246	Crameri et al.	
33.	05/02	6,387,702	Stemmer	
34.	05/03	6,562,594	Short	
35.	11/01	2001/0039014	Bass	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite <sup>1</sup> No.	Publication Date (MM-DD-YYYY)	Document No. Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	36.	09/95	AU703264			
	37.	10/98	AU724698			
	38.	10/97	AU729505			
	39.	06/98	AU732146			
	40.	05/89	EP0316018			
	41.	07/91	EP0439182			
	42.	07/93	EP0552266			
	43.	05/94	EP0596918			
	44.	01/95	EP0633944			
	45.	09/01	EP0876509			
	46.	04/99	EP0911396			
	47.	12/99	EP0963434			

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  <i>(Use as many sheets as necessary)</i>		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

48.	04/01	EP1094108			
49.	05/01	EP1103606			
50.	06/01	EP1108781			
51.	06/01	EP1108783			
52.	09/01	EP1130093			
53.	10/01	EP1138763			
54.	10/01	EP1149904			
55.	10/01	EP1149905			
56.	05/89	EP316018			
57.	03/90	WO90/02809			
58.	08/91	WO91/12341			
59.	04/92	WO92/07075			
60.	02/93	WO93/03183			
61.	06/94	WO94/13804			
62.	07/95	WO95/20039			
63.	08/95	WO95/22625			
64.	02/96	WO96/06188			
65.	03/96	WO96/09411			
66.	12/96	WO96/41865			
67.	02/97	WO97/07205			
68.	06/97	WO97/20078			
69.	06/97	WO97/20950			
70.	10/97	WO97/35966			
71.	04/98	WO98/13485			
72.	06/98	WO98/27230			
73.	09/98	WO98/38297			
74.	10/98	WO98/45331			
75.	10/98	WO98/48024			

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

76.	11/98	WO98/49286		
77.	12/98	WO98/58080		
78.	07/99	WO99/36553		
79.	07/00	WO00/42560		
80.	07/00	WO00/42561		
81.	10/00	WO00/61740		
82.	01/01	WO01/00234		
83.	04/01	WO01/23401		
84.	05/01	WO01/32712		
85.	06/01	WO01/46476		
86.	09/01	WO01/70947		
87.	10/01	WO01/73000		
88.	10/01	WO01/75767		
89.	05/01	WO1103606		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite <sup>1</sup> No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, volume-issue number(s), page(s), publisher, city and/or country where published.	T <sup>6</sup>
	90.	Airaksinen, Antero, et al. "Modified base compositions at degenerate positions of a mutagenic oligonucleotide enhance randomness in site-saturation mutagenesis." Nucleic Acids Research (1998), 26(2), 576-581.	
	91.	Andreas Crameri et al., "Combinatorial Multiple Cassette Mutagenesis Creates All the Permutations of Mutant and Wild-Type Sequences," BioTechniques, vol. 18, No. 2, pp. 194-196 (1995).	
	92.	Arkin and Youvan, "Optimizing nucleotide mixtures to encode specific subsets of amino acids for semi-random mutagenesis," Bio/technology (NY) 10(3):297-300 (Mar. 1992).	
	93.	Arnold F. H. and Moore J.C. Optimizing industrial enzymes by directed evolution. Advances in Biochemical Engineering Biotechnology. 1997;58:1-14, Review.	
	94.	Arnold F. H. When blind is better: protein design by evolution. Nature Biotechnology. Jul. 16, 1998:617-618.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

95.	Arnold R. Oliphant et al., "An efficient method for generating proteins with altered enzymatic properties: Application to $\beta$ -lactamase", Proc. Natl. Acad. Sci. USA, vol. 86, pp. 9094-9098 (Dec. 1989).	
96.	Botstein, D. et al., "Strategies and Applications of in vitro Mutagenesis", Science, Sep. 20, 1985, vol. 229, No. 4719.	
97.	Burks et al., "In vitro scanning saturation mutagenesis of an antibody binding pocket," Proc Natl Acad Sci USA 94(2):412-417 (Jan. 21, 1997).	
98.	Campbell R. K. et al. Assembly and expression of a synthetic gene encoding the bovine glycoprotein hormone alpha-subunit. Molecular and Cellular Endocrinology. 1992;83:195-200.	
99.	Chen and Struhl, "Saturation mutagenesis of a yeast his3 "TATA element": genetic evidence for a specific TATA-binding protein," Proc Natl Acad Sci USA 85(8):2691-2695 (Apr. 1988).	
100.	Chen, G., et al. "In vitro scanning saturation mutagenesis of all the specificity determining residues in an antibody binding site." Protein Engineering 12(4):349-356 (1999)	
101.	Chiang et al., "Mutagenic oligonucleotide-directed PCR amplification (Mod-PCR): an efficient method for generating random base substitution mutations in a DNA sequence element," PCR Methods Appl 2(3):210-217 (Feb. 1993).	
102.	Christian et al., "Simplified methods for construction, assessment and rapid screening of peptide libraries in bacteriophage," J Mol Biol 227(3):711-718 (Oct. 5, 1992).	
103.	Clackson T, et al. Making antibody fragments using phage display libraries. Nature. Aug. 15, 1991 352(6336):624-628.	
104.	Climie, S. et al. Saturation Site-directed Mutagenesis of Thymidylate Synthase. THE Journal of Biological Chemistry 265(31):18776-18779. Nov. 5, 1990.	
105.	Clyde A. Hutchison et al., "Mutagenesis at a Specific Position in a DNA Sequence", The Journal of Biological Chemistry, vol. 253, No. 18, pp. 6551-6560 (Sep. 25, 1978).	
106.	Cohen J. How DNA shuffling works. Science. Ju. 13, 2001;293(5528):237.	
107.	Cramer A., et al. Construction and evolution of antibody-phage libraries by DNA shuffling. Nature Medicine. 2(1):100-102 (Jan. 1996).	
108.	Cramer A., et al. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature. Jan. 15, 1998;391(6664):288-291.	
109.	Cramer A., et al. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nature Biotechnology. Mar. 1996;14(3):315-319.	
110.	Cramer A., et al. Molecular evolution of an arsenate detoxification pathway by DNA shuffling. Nature Biotechnology. May 15, 1997(5):436-438.	
111.	Cunniff and Morgan, "Analysis of heat shock element recognition by saturation mutagenesis of the human HSP70.1 gene promoter," J Biol Chem 268(11):8317-8324	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  <i>(Use as many sheets as necessary)</i>		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

		(Apr. 15, 1993).	
	112.	Cwirla, Steven E. et al., "Peptides on phage: A vast library of peptides for identifying ligands", Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6378-6382, (Aug. 1990).	
	113.	Dennis and Lazarus, "Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display," J Biol Chem 269(35):22129-22136 (Sep. 2, 1994).	
	114.	Derbyshire et al., "A simple and efficient procedure for saturation mutagenesis using mixed oligodeoxynucleotides," Gene 46(2-3):145-152 (1986).	
	115.	Goff et al., "Efficient saturation mutagenesis of a pentapeptide coding sequence using mixed oligonucleotides," DNA 6(4):381-388 (Aug. 1987).	
	116.	Gram H., et al. In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. Proc. National. Acad. Sci. 89(8):3576-80, (Apr, 1992).	
	117.	Griffiths A. D., et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO Journal. 1994, 13: 3245-3260.	
	118.	Harlow P. H., et al. Construction of linker-scanning mutation using the polymerase chain reaction. Methods in Molecular Biology. 31:87-96 (1994).	
	119.	Hayden M.A. and Mandecki W. Gene synthesis by serial cloning of oligonucleotides. DNA. Oct. 1988; 7(8):571-7.	
	120.	Higuchi R., et al. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 16(15):7351-67 (Aug., 1988).	
	121.	Hill, D.E. et al., "Mutagenesis with Degenerate Oligonucleotides: An Efficient Method for Saturating a Defined DNA Region with Base Pair Substitutions", Methods in Enzymology, vol. 155, pp. 558-569 (1987).	
	122.	Ho S.N., et al. DNA and Protein Engineering Using the Polymerase Chain Reaction. DNA Protein Engineering Techniques 2(2):50-55, (1990).	
	123.	Ho S.N., et al. Site-directed mutagensis by overlap extension using the polymerase chain reaction. Gene 77:51-59, (Apr., 1989).	
	124.	Horwitz and DiMaio, "Saturation mutagenesis using mixed oligonucleotides and M13 templates containing uracil," Methods Enzymol 185:599-611 (1990).	
	125.	Houghten, Richard A. "General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids", Proc. Natl. Acad. Sci. USA, vol. 82, pp. 5131-5135 (Aug. 1985).	
	126.	Ihara et al., "Requirement of the Pro-Cys-His-Arg sequence for O <sup>6</sup> -methylguanine-DNA methyltransferase activity revealed by saturation mutagenesis with negative and positive screening," Mol Gen Genet 243(4):379-389 (May 25, 1994).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO		Application Number: 10/644,410	Filing Date: August 20, 2003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

127.	Imamura T., et al. Identification of the domain within fibroblast growth factor-1 responsible for heparin-dependence. <i>Biochimica et Biophysica Acta</i> . Apr. 28, 1995;1266(2):124-30.	
128.	Jenkins, B.J., et al. Saturation mutagenesis of the $\beta$ subunit of the human granulocyte-macrophage colony-stimulating factor receptor shows clustering of constitutive mutations, activation of ERK MAP kinase and STAT pathways, and differential $\beta$ subunit tyrosine phosphorylation. <i>Blood</i> 92(6):1989-2002 (September 15, 1998)	
129.	Joyce G.F. Directed molecular evolution. <i>Scientific America</i> . 267(6):90-7, (Dec, 1992).	
130.	Levichklin, et al. A new approach to construction of hybrid genes: homolog recombination method. <i>Molecular Biology</i> : 29(5)1:572-577 (Jul.-Aug. 1995).	
131.	Little, J.W. "Saturation mutagenesis of specific codons: elimination of molecules with stop codons from mixed pools of DNA," <i>Gene</i> 88(1):113-115 (Mar. 30, 1990).	
132.	Matteucci, M.D. et al., "Targeted random mutagenesis: the use of ambiguously oligonucleoides to mutagenize sequences immediately 5' of an ATG initiation codon", <i>Nucleic Acids Research</i> , vol. 11, pp. 3113-3121 (Nov. 10, 1983).	
133.	McNeil, J.B. et al., "Saccharomyces cerevisiae CYC1 mRNA 5'-End Positioning: Analysis by In Vitro Mutagenesis, Using Synthetic Duplexes with Random Mismatch Base Pairs," <i>Molecular and Cellular Biology</i> , vol. 5, No. 12, pp. 3545-3551 (Dec. 1985).	
134.	Melnikov A. and Youngman PJ. Random mutagenesis by recombinational capture of PCR products in <i>Bacillus subtilis</i> and <i>Acinetobacter Calcoaceticus</i> . <i>Nucleic Acids Res.</i> Feb. 15, 1999;27(4):1056-62.	
135.	Milkman, Roger et al., "Clustered Third-Base Substitutions Among Wild Strains of <i>Escherichia coli</i> ," <i>Science</i> , vol. 221, pp. 378-380 (Jul. 22, 1983).	
136.	Morris and McIvor, "Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance," <i>Biochem Pharmacol</i> 47(7):1207-1220 (Mar. 29, 1994).	
137.	Murray, Richard et al., "Saturation mutagenesis of a major histocompatibility complex protein domain: Identification of a single conserved amino acid important for allore cognition", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 85, pp. 3535-3539 (May 1988).	
138.	Murray, Richard et al., Random oligonucleotide mutagenesis: application to a large protein coding sequence of a major histocompatibility complex class I gene, H-2DP, <i>Nucleic Acids Research</i> , vol. 16, No. 20, pp. 9761-9773 (1988).	
139.	Myers, R.M. et al., "A General Method for Saturation Mutagenesis of Cloned DNA Fragments", <i>Science</i> , vol. 229, pp. 242-247 (Jul. 19, 1985).	
140.	O'Donohue, M.J., and G. Geoff Kneale. A method for introducing site-specific mutations using oligonucleotide primers and its application to site-saturation mutagenesis. <i>Molecular Biotechnology</i> 6:179-89. 1996.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  <i>(Use as many sheets as necessary)</i>		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

141.	Olesen and Kielland-Brandt, "Altering substrate preference of carboxypeptidase Y by a novel strategy of mutagenesis eliminating wild type background," <i>Protein Eng</i> 6(4):409-415 (Jun. 1993).	
142.	Olins et al., "Saturation mutagenesis of human interleukin-3," <i>J Biol Chem</i> 270(40):23754-23760 (Oct. 6, 1995).	
143.	Oliphant et al., "Cloning of random-sequence oligodeoxynucleotides," <i>Gene</i> 44(2-3):177-183 (1986).	
144.	Osuna et al., "Combinatorial mutagenesis of three major groove-contacting residues of EcoRI: single and double amino acid replacements retaining methyltransferase-sensitive activities," <i>106(1):7-12</i> (Sep. 30, 1991).	
145.	Pompon D. and Nicolas A. Protein engineering by cDNA recombination in yeasts: Shuffling of mammalian cytochrome p450 functions. <i>Gene</i> 83(1):15-24 (Nov., 1989).	
146.	Punnonen J. Molecular breeding of allergy vaccines and antiallergic cytokines. <i>Int Arch Allergy Immunol</i> . Mar. 2000;121(3):173-82, Review.	
147.	Raillard S., et al. Novel enzyme activities and functional plasticity revealed by recombining highly homologous enzymes. <i>Chemistry Biology</i> . 2001 Sep.;8(9):891-898.	
148.	Reidhaar-Olson et al., "Random mutagenesis of protein sequences using oligonucleotide cassettes," <i>Methods Enzymol</i> 208:564-586 (1991).	
149.	Roberts et al., "Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage," <i>Proc Natl Acad Sci USA</i> 89(6):2429-2433 (Mar. 15, 1992).	
150.	Saiki, R.K., et al. Enzymatic amplification of $\beta$ -globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. <i>Science</i> 230(4732):1350-1354, (Dec. 1985).	
151.	Schultz, S.C., and J.H. Richards. Site-saturated studies of $\beta$ -lactamase: production and characterization of mutant $\beta$ -lactamases with all possible amino acid substitutions at residue 71. <i>Proc Natl Acad Sci USA</i> 83:1588-92. March 1986.	
152.	Shao, Z., et al. Random-priming in vitro recombination: an effective tool for directed evolution. <i>Nucleic Acids Res</i> . Jan. 15, 1998; 26(2):681-3.	
153.	Sherman et al., "Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center," <i>J Biol Chem</i> 267(11):7588-7595 (Apr. 15, 1992).	
154.	Shortle, David et al., "Gap misrepair mutagenesis: Efficient site-directed induction of transition, transversion, and frameshift mutations in vitro", <i>Proc. Natl. Acad. Sci. USA</i> , vol. 79, pp. 1588-1592, (Mar. 1982).	
155.	Sikorski R.S. and Boeke J.D. In vitro mutagenesis and plasmid shuffling: from cloned gene to mutant yeast. <i>Methods Enzymol</i> . 194:302-318 (1991).	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Application Number: 10/644,410	Filing Date: August 20, 2003
First Named Inventor: Short			
Docket Number: D1460-32US			
Examiner Name		Art Unit To Be Assigned	
Mailing Date: October 12, 2005			

156.	Singh et al., "Saturation mutagenesis of the octopine synthase enhancer: correlation of mutant phenotypes with binding of a nuclear protein factor," Proc Natl Acad Sci USA 86(10):3733-3737 (May 1989).		
157.	Sirotnik, K. "Advantages to mutagenesis techniques generating populations containing the complete spectrum of single codon changes," J Theor Biol 123(3):261-279 (Dec. 7, 1986).		
158.	Sirotnik, K. "A computer program to display codon changes caused by mutagenesis," Comput Appl Biosci 4(2):243-247 (Apr. 1988).		
159.	Smith, Michael "In Vitro Mutagenesis", Ann. Rev. Genet., 19:423-62 (1985).		
160.	Soteropoulos and Perlin, "Genetic probing of the stalk segments associated with M2 and M3 of the plasma membrane H <sup>+</sup> -ATPase from <i>Saccharomyces cerevisiae</i> ," J Biol Chem 273(41):26426-26431 (Oct. 9, 1998).		
161.	Soteropoulos et al., "Molecular genetic probing of energy coupling by the yeast plasma membrane proton pump," Acta Physiol Scand 643:115-122 (Aug. 1998).		
162.	Stemmer W.P., et al. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides, Gene. Oct. 16, 1995; 164(1):49-53.		
163.	Tsiang et al., "Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo," Biochemistry 35(51):16449-16457 (Dec. 24, 1996).		
164.	Warren et al., "A rapid screen of active site mutants in glycaminamide ribonucleotide transformylase," Biochemistry 35(27):8855-8862 (Jul. 9, 1996).		
165.	Weber H. and Weissmann C. Formation of genes coding for hybrid proteins by recombination between related, cloned genes in <i>E.coli</i> . Nucleic Acids Res. 11(16):5661-69 (Aug. 1983).		
166.	Weiner et al., "A method for the site-directed mono- and multi-mutagenesis of double-stranded DNA," Gene 126(1):35-41 (Apr. 15, 1993).		
167.	Wells, J.A. et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites", Gene, 34, 315-323 (1985).		
168.	White et al., "Improved thermostability of the North American firefly luciferase: saturation mutagenesis at position 354," Biochem J 319 (Pt 2):343-350 (Oct. 15, 1996).		
169.	Yelton et al., "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis," J Immunol 155(4):1994-2004 (Aug. 15, 1995).		
170.	Zakour, Richard A. et al., "Site-specific mutagenesis by error-directed DNA synthesis", Nature, vol. 295, pp. 708-710 (Feb. 25, 1982).		
171.	Zhang J.H., et al. Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening. Proc National Academy Science U.S.A. Apr. 29, 1997;94(9):4504-9.		
172.	Zilliacus et al., "Evolution of distinct DNA-binding specificities within the nuclear		

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  <i>(Use as many sheets as necessary)</i>		Application Number: 10/644,410	Filing Date: August 20, 2003
		First Named Inventor: Short	
		Docket Number: D1460-32US	
		Examiner Name	Art Unit To Be Assigned
		Mailing Date: October 12, 2005	

		receptor family of transcription factors," Proc Natl Acad Sci USA 91(10):4175-4179 (May 10, 1994).	
	173.	Zoller M.J. New recombinant DNA methodology for protein engineering. Current Opinion Biotechnology 1992. 3(4):348-54. Review.	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at <a href="http://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.	
SEND COMPLETED FORM TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	